Table 1. Demographic Characteristics and Disease Metrics of the Study Cohort.
| Characteristic or Disease Metrica | Light Therapy Group, Mean (SD) | P Value | |
|---|---|---|---|
| Bright | Dim-Red | ||
| Age, y | 62.31 (10.83) | 64.07 (8.89) | .63 |
| Sex, male/female | 8/8 | 5/10 | .47 |
| Disease duration | 5.94/3.57 | 8.38/3.71 | .08 |
| Hoehn and Yahr stage, No. (%) | |||
| 2 | 14 (87.5) | 10 (66.67) | .53 |
| 2.5 | 1 (6.25) | 3 (20.00) | |
| 3 | 1 (6.25) | 1 (6.67) | |
| 4 | 1 (6.67) | ||
| UPDRS | 39.69 (15.85) | 45.07 (20.15) | .63 |
| I | 1.75 (0.86) | 2.27 (1.49) | .36 |
| II | 10.44 (5.23) | 10.40 (7.13) | .68 |
| III | 24.75 (11.26) | 29.13 (12.43) | .33 |
| IV | 2.75 (2.24) | 3.27 (2.12) | .36 |
| LED | 492.13 (362.08) | 540.27 (233.41) | .67 |
| Mini-Mental State Examination score | 29.13 (1.19) | 29.13 (1.06) | .86 |
| Beck Depression Inventory score | 8.31 (3.63) | 8.27 (4.71) | .98 |
| Epworth Sleepiness Scale score | 15.81 (3.10) | 15.47 (2.59) | .81 |
| Pittsburgh Sleep Quality Index | 7.88 (4.11) | 8.87 (2.83) | .44 |
| Parkinson’s Disease Sleep Scale score | 97.24 (22.49) | 95.11 (19.86) | .78 |
| Fatigue Severity Scale score | 41.62 (12.62) | 37.00 (9.10) | .34 |
| Parkinson’s Disease Questionnaire-39 score | 41.46 (19.30) | 36.80 (19.72) | .58 |
| Central nervous system–active medications | Sertraline, 50 mg (n = 1) Escitalopram, 10-30 mg (n = 2) |
Bupropion, 300 mg (n = 1) Escitalopram, 30 mg (n = 1) |
|
Abbreviations: LED, levodopa equivalent dose; UPDRS, Unified Parkinson’s Disease Rating Scale.
a
The scales are explained in the Study Population subsection of the Methods section.